Peripheral blood progenitor cells (PBPC) are increasingly being used instead of bone marrow in autologous transplantation for hematologic malignancies. 1 This approach shortens the period of pancytopenia and may reduce the risks of infection and bleeding. 
CD34
+ cell dose between 2 and 5 × 10 6 /kg as being the optimal for rapid engraftment. A threshold value of 1.0 ϫ 10 6 /kg CD34 + cells has been suggested as the minimum number of cells required for autologous transplantation. 3 To obtain an adequate harvest there is evidence that more CD34 + cells can be collected following the administration of chemotherapy and growth factors than after growth factors alone. 4, 5 Among the regimens with chemotherapy and growth factors, the combination of CY and G-CSF or GM-CSF has been the gold-standard for PBPC collection, although other schemes have been used for this purpose in lymphoma patients, and some of them could be more effective.
We have explored an original combination, IAPVP-16 plus G-CSF, as chemotherapy to decrease tumor burden 6 and also for PBPC mobilization. In this study we analyze the predictive factors influencing the quality of harvests obtained with this regimen, and we investigate whether the number of CD34 + cells in peripheral blood (PB) adequately predicts the optimum time to start leukaphereses.
Materials and methods

Characteristics of the patients
Forty-five patients with relapsed or refractory lymphoma underwent PBPC harvests after salvage chemotherapy with the IAPVP-16 protocol followed by G-CSF. Patients were treated between February 1991 and March 1997, and their characteristics pre-salvage chemotherapy and mobilization are shown in Table 1 . Underlying disease was diagnosed according to the REAL classification. Thirty-four patients had non-Hodgkin's lymphoma (follicular (n = 16), mantle cell (n = 2), diffuse large cell (n = 11) and others (n = 5)), nine patients had Hodgkin's disease and two had multiple myeloma. Peripheral granulocyte and platelet counts premobilization were р1.5 ϫ 10 9 /l and р150 ϫ 10 9 /l, in nine and 10 patients, respectively. Sixteen patients had received one chemotherapy regimen before IAPVP-16 and 29 more than one. At mobilization, 32 patients were in complete or partial response and 13 in chemosensitive relapse. Of the 45 patients, 17 had histopathological evidence of bone marrow involvement at mobilization. The median interval between diagnosis and mobilization was 17 months (range 7-81). Ten patients had failed previous mobilization attempts (G-CSF plus CY 1.5 g/m 2 in nine cases and the mini-BEAM regimen plus G-CSF in one case).
Mobilization of PBPC
All patients received salvage chemotherapy with the IAPVP-16 protocol which includes: ifosfamide 5 g/m 2 i.v. on day 1; VP-16 100 mg/m 2 i.v. on days 1-3; ara-C 1.2 g/m 2 /12 h i.v. on days 1 and 2; methylprednisolone 80 mg/m 2 i.v. on days 1-5. Recombinant human G-CSF (Filgrastrim; Amgen, Thousand Oaks, CA, USA) was given at a dose of 5 g/kg as a single daily subcutaneous injection, from day 6 of start of chemotherapy until the end of leukaphereses.
Collection and cryopreservation of PBPC
Leukaphereses were started when the patients reached more than 1 ϫ 10 9 WBC/l and PB counts of CD34 + cells exceeded 2.5 per l. MNCs were collected by a continuousflow blood cell separator COBE Spectra (Lakewood, CO, USA) or Fenwal CS-3000 Plus (Baxter, Barcelona, Spain).
A median volume of 15 (8-23) liters was processed per leukapheresis with a flow rate of 60-100 ml/min. Leukaphereses were performed until a minimum target cell dose of 3 ϫ 10 6 /kg CD34 + cells was collected. Each leukapheresis product was cryopreserved with a controlled freezer and stored in liquid nitrogen until the day of transplantation. 7 
In vitro assays
The number of CD34 + cells present in the circulation and in the harvested products was assessed by flow cytometry (PE-8G12; Becton Dickinson, San Jose, CA, USA). Colony-forming units granulocyte-monocyte (CFU-GM) were measured according to the Pike and Robinson agar technique. 8 Total numbers of colonies (Ͼ50 cells) were counted under an inverted microscope after 14 days.
Statistical analysis
Differences between categorical variables were measured by the chi-square test. Two multivariate logistic regression models were created to ascertain which variables significantly predicted the achievement of an 'adequate' (more than 2.0 ϫ 10 6 /kg CD34 + cells) and 'optimal' (more than 5.0 ϫ 10 6 /kg CD34 + cells) harvest. An univariate linear regression test was used to study the relation between logarithm transformation of CD34 + cells yield and peripheral CD34 + cells and CFU-GM collected in each leukapheresis. We considered the results as statistically significant when P values were less than 0.05.
Results
We performed 45 mobilization procedures, with a median of two consecutive leukaphereses (1-4) on an outpatient basis. The mobilization regimen was well tolerated. The median durations of neutropenia (Ͻ0.5 × 10 9 /l) and thrombocytopenia (Ͻ20 × 10 9 /l) were 5 (1-12) and 3 (1-15) days, respectively. Non-hematologic toxicities were well tolerated. There were 19 episodes of neutropenic fever (14 patients required re-admission prior to apheresis) and two cases of grade 2 neurologic toxicity. The toxic re-admission rate was 31% with a mean increase in hospitalisation of 2 days. Overall results of leukaphereses and PBPC collections are summarized in Table 2 . Harvesting was started at a median of 12 (11) (12) (13) (14) The median number of CD34 + cells harvested in the 10 patients with prior mobilization failures was 4.14 ϫ 10 6 /kg (1.14-5.48). In seven of these cases more than 2 ϫ 10 6 /kg 
CD34
+ cells were collected,with one to three aphereses. Table 3 shows clinical and mobilization data of these 10 patients. Table 4 shows the results of the univariate analysis of factors possibly influencing an adequate and optimal harvest after IAPVP-16 plus G-CSF. A previous mobilization failure and a pretreatment platelet count Ͻ150 ϫ 10 9 /l negatively influenced the yield of these two CD34 + cell targets, while prior radiotherapy and a time interval of more than 1 year from diagnosis to mobilization negatively influenced the first and second targets, respectively. Nine of 10 (90%) patients with a low platelet count have received more than six cycles of chemotherapy, and only 20 of 35 (57%) patients with a normal platelet count have been so heavily pre-treated (P = 0.05).
In two logistic regression models including the same variables, a premobilization platelet count Ͻ150 ϫ 10 9 /l Table 3 Essential clinical and mobilization data of 10 patients with previous mobilization failures Bone Marrow Transplantation and previous failure of mobilization were associated with decreased CD34 + cell yields in both adequate (P = 0.04 and P = 0.03) and optimal (P = 0.04 and P = 0.007) mobilizers.
A good correlation was found between logarithm transformation of early morning circulating CD34
+ cells/l in PB on the day of leukapheresis and the number of CD34 + cells obtained per leukapheresis (r = 0.93, P Ͻ 0.001), as is shown in Figure 1 . There was also a very good correlation between the CD34 + cells obtained in each leukapheresis product and the CFU-GM content (r = 0.73, P = Ͻ 0.001). With these data we calculated a linear regression equation to predict the number of circulating CD34
+ cells required to obtain more than 2 ϫ 10 6 CD34 + cells/kg with a single leukapheresis. A threshold early morning PB CD34
+ count of 17 cells/l predicted an adequate harvest in 92% of cases. This threshold was reached by 33 patients (73%).
Discussion
The results of this study indicate that IAPVP-16 chemotherapy plus G-CSF is a highly effective regimen for mobilization of PBPC in patients with advanced lymphoma. These results confirm earlier observations in smaller numbers of patients, 9 even when a lower dose of G-CSF was used after chemotherapy. 10 An additional advantage is the effectiveness of IAPVP-16 as salvage therapy in patients with low-grade lymphoma, 11 thus allowing the simultaneous reduction of tumor burden and harvesting of PBPC in preparation for an autologous stem cell transplant. Of special interest is the marked predictability of the first day of mobilization, which occurred in all cases between days 11 and 14 of therapy and in 80% on day 12, thus allowing the exact scheduling of the aphereses procedures and reducing any last minute changes that alter the routine work of the apheresis unit and stem cell processing laboratory. As previously reported in detail, 11 the regimen has little extrahematologic toxicity, although severe pancytopenia occurs in all cases and neutropenic fever occurred in 42% of treatment cycles requiring hospital admission in 31%.
To analyze the efficacy of this mobilization regimen we chose two target doses of harvested CD34 + cells. An adequate and an optimal harvest were defined as above 2 x 10 6 /kg and 5 x 10 6 /kg CD34 + cells, respectively, since most studies have identified these two thresholds as being the minimum safe number of PBPC and the optimal number for rapid trilineage engraftment, respectively. 12,13 More than 90% of our patients achieved an adequate and 70% an optimal harvest, including 7/10 who had failed a previous mobilization attempt. In nine of these 10 patients the previous mobilization chemotherapy used was CY 1.5 g/m 2 . It is possible that a more intensive dose of CY would have had the same effect as IAPVP-16 in mobilizing progenitor cells. Nevertheless, these high harvests with a median of only two leukapheresis procedures make this regimen especially attractive for patients who are included in tandem transplant protocols or when CD34
+ cell selection of PBPC is planned. Similar results have been reported with other combination chemotherapy regimens including ifosfamide and etoposide plus G-CSF. + cells but with a median of seven apheresis procedures. The median yield per procedure thus appears to be higher with our regimen, although direct comparisons should be avoided since the patient populations may in fact differ in relevant prognostic factors for mobilization efficacy as well as technical differences in venous access and/or the apheresis procedure itself.
Of particular importance in clinical practice is the identification of patients who have an increased risk of failing to mobilize PBPC. In our series of patients factors adversely affecting the achievement of an adequate and/or optimal harvest were a previous mobilization failure, a baseline platelet count below 150 x 10 9 /l, prior radiotherapy and a time interval from diagnosis to mobilization of more than 1 year. These prognostic factors have been identified in previous studies, 4, [16] [17] [18] [19] [20] although well-known variables such as the number of prior courses of chemotherapy were not significant in our study. 21 It is interesting that our thrombopenic patients were heavily pre-treated in 90% of cases. Probably, thrombopenia is a very good index of bone marrow damage secondary to previous chemotherapy, and predicts with high accuracy poor mobilizations. This parameter, however, has been previously analyzed only by Weaver et al, 20 who found it to be the most important predictive factor in a large group of patients mobilized with CY, etoposide and G-CSF. We found a good correlation between the early morning PB CD34
+ cell count and the content of CD34 + cells (r = 0.93, P Ͻ 0.001) and CFU-GM (r = 0.73, P Ͻ 0.001) in the same day harvested product. This correlation has been observed by other authors 15, [22] [23] [24] and forms the basis of the widely accepted routine practice of guiding the timing of leukaphereses based on the daily PB CD34 + counts. A threshold of 17 CD34
+ cells/l in PB predicted the achievement of an adequate harvest with a single leukapheresis in most patients (31/33 patients who reached this threshold). Other authors have identified such threshold values for a target cell dose of 1-3 x 10 6 /kg (see Table 5 ). As seen, the threshold count varies from one study to another, as well as the percentage of patients who actually reach this value. Again, direct comparisons should be avoided since the patient populations and mobilization regimens probably differ in relevant prognostic factors, as well as technical differences in the systems of CD34 + cell quantification, different priming methods, different volume processed per leukapheresis, etc. In summary, IAPVP-16 chemotherapy followed by G-CSF is a highly effective mobilization regimen for patients with advanced lymphoma. Effective tumor cytoreduction can be coupled with a very predictable PBPC harvesting, and most patients who will not obtain an adequate harvest can be identified by simple characteristics such as prior mobilization failures and a baseline low platelet count. Additionally, the early morning CD34 + PB count highly correlates with the cell yield in the same day leukapheresis procedure.
